

CHLD0071: Molecular and Clinical Aspects of Childhood Cancers

[View Online](#)

Azarova, Anna M., et al. 'Emerging Importance of ALK in Neuroblastoma'. *Seminars in Cancer Biology*, vol. 21, no. 4, Oct. 2011, pp. 267–75, <https://doi.org/10.1016/j.semcancer.2011.09.005>.

Beierle, Elizabeth A. 'MYCN, Neuroblastoma and Focal Adhesion Kinase (FAK)'. *Frontiers in Bioscience (Elite Edition)*, vol. 3, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171213/>.

Bell, Emma, et al. 'MYCN Oncoprotein Targets and Their Therapeutic Potential'. *Cancer Letters*, vol. 293, no. 2, July 2010, pp. 144–57, <https://doi.org/10.1016/j.canlet.2010.01.015>.

Bender, Sebastian, et al. 'Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas'. *Cancer Cell*, vol. 24, no. 5, Nov. 2013, pp. 660–72, <https://doi.org/10.1016/j.ccr.2013.10.006>.

Berry, Teeara, et al. 'The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma'. *Cancer Cell*, vol. 22, no. 1, July 2012, pp. 117–30, <https://doi.org/10.1016/j.ccr.2012.06.001>.

Bleggi-Torres, Luiz Fernando, et al. 'Accuracy of the Smear Technique in the Cytological Diagnosis of 650 Lesions of the Central Nervous System'. *Diagnostic Cytopathology*, vol. 24, no. 4, Apr. 2001, pp. 293–95, <https://doi.org/10.1002/dc.1062>.

Blümcke, Ingmar, et al. 'Low-Grade Epilepsy-Associated Neuroepithelial Tumours — the 2016 WHO Classification'. *Nature Reviews Neurology*, vol. 12, no. 12, Dec. 2016, pp. 732–40, <https://doi.org/10.1038/nrneurol.2016.173>.

Brodeur, Garrett M. 'Neuroblastoma: Biological Insights into a Clinical Enigma'. *Nature Reviews Cancer*, vol. 3, no. 3, Mar. 2003, pp. 203–16, <https://doi.org/10.1038/nrc1014>.

Brodeur, Garrett M., and Rochelle Bagatell. 'Mechanisms of Neuroblastoma Regression'. *Nature Reviews Clinical Oncology*, vol. 11, no. 12, Dec. 2014, pp. 704–13, <https://doi.org/10.1038/nrclinonc.2014.168>.

Brown, Christine E., et al. 'Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy'. *New England Journal of Medicine*, vol. 375, no. 26, Dec. 2016, pp. 2561–69, <https://doi.org/10.1056/NEJMoa1610497>.

Buckner, Tyler, et al. 'The Autopsy in Pediatrics and Pediatric Oncology: A Single-Institution

Experience'. *Pediatric and Developmental Pathology*, vol. 9, no. 5, Sept. 2006, pp. 374–80, <https://doi.org/10.2350/06-02-0047.1>.

Burkhart, C. A., et al. 'Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma'. *JNCI Journal of the National Cancer Institute*, vol. 95, no. 18, Sept. 2003, pp. 1394–403, <https://doi.org/10.1093/jnci/djg045>.

Chen, L., et al. 'P53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma'. *Cancer Research*, vol. 70, no. 4, Feb. 2010, pp. 1377–88, <https://doi.org/10.1158/0008-5472.CAN-09-2598>.

Chhabda, Sahil, et al. 'The 2016 World Health Organization Classification of Tumours of the Central Nervous System: What the Paediatric Neuroradiologist Needs to Know'. *Quantitative Imaging in Medicine and Surgery*, vol. 6, no. 5, Oct. 2016, pp. 486–89, <https://doi.org/10.21037/qims.2016.10.01>.

Children's Cancer Statistics | Cancer Research UK.

<http://www.cancerresearchuk.org/health-professional/cancer-statistics/childrens-cancers>.

Cossu, Irene, et al. 'Neuroblastoma-Targeted Nanocarriers Improve Drug Delivery and Penetration, Delay Tumor Growth and Abrogate Metastatic Diffusion'. *Biomaterials*, vol. 68, Nov. 2015, pp. 89–99, <https://doi.org/10.1016/j.biomaterials.2015.07.054>.

Ellison, David W., et al. 'β-Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee'. *Journal of Clinical Oncology*, vol. 23, no. 31, Nov. 2005, pp. 7951–57, <https://doi.org/10.1200/JCO.2005.01.5479>.

Evans, A. E., et al. 'Do Infants with Stage IV-S Neuroblastoma Need Treatment?' *Archives of Disease in Childhood*, vol. 56, no. 4, Apr. 1981, pp. 271–74, <https://doi.org/10.1136/adc.56.4.271>.

Fisher, Jonathan, et al. 'Avoidance of On-Target Off-Tumor Activation Using a Co-Stimulation-Only Chimeric Antigen Receptor'. *Molecular Therapy*, vol. 25, no. 5, May 2017, pp. 1234–47, <https://doi.org/10.1016/j.ymthe.2017.03.002>.

Garrett M. Brodeur, Robert C. Seeger, Manfred Schwab, Harold E. Varmus and J. Michael Bishop. 'Amplification of N-Myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage'. *Science*, vol. 224, no. 4653, 1984, pp. 1121–24, <http://www.jstor.org/stable/1692440>.

Ghorashian, Sara, et al. 'Open Access? Widening Access to Chimeric Antigen Receptor (CAR) Therapy for ALL'. *Experimental Hematology*, vol. 66, Oct. 2018, pp. 5–16, <https://doi.org/10.1016/j.exphem.2018.07.002>.

Gibson, Paul, et al. 'Subtypes of Medulloblastoma Have Distinct Developmental Origins'. *Nature*, vol. 468, no. 7327, Dec. 2010, pp. 1095–99, <https://doi.org/10.1038/nature09587>.

Goschzik, Tobias, et al. 'Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma'. *Journal of Neuropathology & Experimental Neurology*, Jan. 2017, <https://doi.org/10.1093/jnen/nlw116>.

Greaves, Mel F., and Joe Wiemels. 'Origins of Chromosome Translocations in Childhood Leukaemia'. *Nature Reviews Cancer*, vol. 3, no. 9, Sept. 2003, pp. 639–49, <https://doi.org/10.1038/nrc1164>.

Guglielmi, L., et al. 'MYCN Gene Expression Is Required for the Onset of the Differentiation Programme in Neuroblastoma Cells'. *Cell Death & Disease*, vol. 5, no. 2, Feb. 2014, pp. e1081–e1081, <https://doi.org/10.1038/cddis.2014.42>.

Gump, Jacob M., et al. 'Identification of Targets for Rational Pharmacological Therapy in Childhood Craniopharyngioma'. *Acta Neuropathologica Communications*, vol. 3, no. 1, Dec. 2015, <https://doi.org/10.1186/s40478-015-0211-5>.

Hanahan, Douglas, and Robert A. Weinberg. 'Hallmarks of Cancer: The Next Generation'. *Cell*, vol. 144, no. 5, Mar. 2011, pp. 646–74, <https://doi.org/10.1016/j.cell.2011.02.013>.

Hanahan, Douglas, and Robert A. Weinberg. 'The Hallmarks of Cancer'. *Cell*, vol. 100, no. 1, Jan. 2000, pp. 57–70, [https://doi.org/10.1016/S0092-8674\(00\)81683-9](https://doi.org/10.1016/S0092-8674(00)81683-9).

Hashizume, Rintaro, et al. 'Pharmacologic Inhibition of Histone Demethylation as a Therapy for Pediatric Brainstem Glioma'. *Nature Medicine*, vol. 20, no. 12, Dec. 2014, pp. 1394–96, <https://doi.org/10.1038/nm.3716>.

Hasle, Henrik, and Charlotte M. Niemeyer. 'Advances in the Prognostication and Management of Advanced MDS in Children'. *British Journal of Haematology*, vol. 154, no. 2, July 2011, pp. 185–95, <https://doi.org/10.1111/j.1365-2141.2011.08724.x>.

Hill, Rebecca M., et al. 'Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease'. *Cancer Cell*, vol. 27, no. 1, Jan. 2015, pp. 72–84, <https://doi.org/10.1016/j.ccell.2014.11.002>.

Hourigan, Christopher S., and Judith E. Karp. 'Minimal Residual Disease in Acute Myeloid Leukaemia'. *Nature Reviews Clinical Oncology*, vol. 10, no. 8, Aug. 2013, pp. 460–71, <https://doi.org/10.1038/nrclinonc.2013.100>.

Huang, M., and W. A. Weiss. 'Neuroblastoma and MYCN'. *Cold Spring Harbor Perspectives in Medicine*, vol. 3, no. 10, Oct. 2013, pp. a014415–a014415, <https://doi.org/10.1101/cshperspect.a014415>.

Huber, Katrin, et al. 'The Development of the Chromaffin Cell Lineage from the Neural Crest'. *Autonomic Neuroscience*, vol. 151, no. 1, Nov. 2009, pp. 10–16, <https://doi.org/10.1016/j.autneu.2009.07.020>.

Hubert, Christopher G., et al. 'A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found'. *Cancer Research*, vol. 76, no. 8, Apr. 2016, pp. 2465–77, <https://doi.org/10.1158/0008-5472.CAN-15-2402>.

Hunger, Stephen P., and Charles G. Mullighan. 'Acute Lymphoblastic Leukemia in Children'. *New England Journal of Medicine*, vol. 373, no. 16, Oct. 2015, pp. 1541–52, <https://doi.org/10.1056/NEJMra1400972>.

International Agency for Research on Cancer. WHO Classification of Tumours of the Central Nervous System. Edited by David N. Louis et al., Revised 4th edition, International Agency for Research on Cancer, 2016.

Johnson, Laura A., and Carl H. June. 'Driving Gene-Engineered T Cell Immunotherapy of Cancer'. *Cell Research*, vol. 27, no. 1, Jan. 2017, pp. 38–58, <https://doi.org/10.1038/cr.2016.154>.

Kirsti Sirkiä, Ulla M. Saarinen-Pihkala, Liisa Hovi, Hannu Sariola. 'Autopsy in Children with Cancer Who Die While in Terminal Care'. *Medical and Pediatric Oncology*, vol. 30, no. 5, 1998, pp. 284–89, [https://doi.org/10.1002/\(SICI\)1096-911X\(199805\)30:5<284::AID-MPO4>3.0.CO;2-B](https://doi.org/10.1002/(SICI)1096-911X(199805)30:5<284::AID-MPO4>3.0.CO;2-B).

Klebanoff, Christopher A., et al. 'Prospects for Gene-Engineered T Cell Immunotherapy for Solid Cancers'. *Nature Medicine*, vol. 22, no. 1, Jan. 2016, pp. 26–36, <https://doi.org/10.1038/nm.4015>.

Koebel, Catherine M., et al. 'Adaptive Immunity Maintains Occult Cancer in an Equilibrium State'. *Nature*, vol. 450, no. 7171, Dec. 2007, pp. 903–07, <https://doi.org/10.1038/nature06309>.

Korshunov, Andrey Sturm, Dominik Ryzhova, Marina Hovestadt, Volker Gessi, Marco. 'Embryonal Tumor with Abundant Neuropil and True Rosettes (ETANTR), Ependymoblastoma, and Medulloepithelioma Share Molecular Similarity and Comprise a Single Clinicopathological Entity'. *Acta Neuropathologica*, vol. 128, no. 8, pp. 279–89, <https://search.proquest.com/docview/1545765655?OpenUrlRefId=info:xri/sid:primo&aaccountid=14511>.

Kotrova, Michaela, et al. 'Is Next-Generation Sequencing the Way to Go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?' *Molecular Diagnosis & Therapy*, vol. 21, no. 5, Oct. 2017, pp. 481–92, <https://doi.org/10.1007/s40291-017-0277-9>.

Larson, Jon D., et al. 'Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression'. *Cancer Cell*, Dec. 2018, <https://doi.org/10.1016/j.ccell.2018.11.015>.

Lee, Tong Ihn, and Richard A. Young. 'Transcriptional Regulation and Its Misregulation in Disease'. *Cell*, vol. 152, no. 6, Mar. 2013, pp. 1237–51, <https://doi.org/10.1016/j.cell.2013.02.014>.

Lewis, P. W., et al. 'Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma'. *Science*, vol. 340, no. 6134, May 2013, pp. 857–61, <https://doi.org/10.1126/science.1232245>.

Liu, Zhihui, and Carol J. Thiele. 'ALK and MYCN: When Two Oncogenes Are Better than One'. *Cancer Cell*, vol. 21, no. 3, Mar. 2012, pp. 325–26, <https://doi.org/10.1016/j.ccr.2012.03.004>.

Lord, Christopher J., and Alan Ashworth. 'Biology-Driven Cancer Drug Development: Back to the Future'. *BMC Biology*, vol. 8, no. 1, 2010, <https://doi.org/10.1186/1741-7007-8-38>.

- Lu, Benjamin, et al. 'Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials'. *Cancers*, vol. 8, no. 9, Sept. 2016, <https://doi.org/10.3390/cancers8090082>.
- Mackall, Crystal L., et al. 'Immune-Based Therapies for Childhood Cancer'. *Nature Reviews Clinical Oncology*, vol. 11, no. 12, Dec. 2014, pp. 693–703, <https://doi.org/10.1038/nrclinonc.2014.177>.
- Majzner, Robbie G., et al. 'Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers'. *Cancer Cell*, vol. 31, no. 4, Apr. 2017, pp. 476–85, <https://doi.org/10.1016/j.ccell.2017.03.002>.
- Marabelle, Aurélien, et al. 'Hypercalcemia and 13-
-Retinoic Acid in Post-Consolidation Therapy of Neuroblastoma'. *Pediatric Blood & Cancer*, vol. 52, no. 2, Feb. 2009, pp. 280–83, <https://doi.org/10.1002/pbc.21768>.
- Martinez-Barbera, Juan Pedro, and Cynthia L. Andoniadou. 'Concise Review: Paracrine Role of Stem Cells in Pituitary Tumors: A Focus on Adamantinomatous Craniopharyngioma'. *STEM CELLS*, vol. 34, no. 2, Feb. 2016, pp. 268–76, <https://doi.org/10.1002/stem.2267>.
- Martinez-Barbera, Juan Pedro, and Rolf Buslei. 'Adamantinomatous Craniopharyngioma: Pathology, Molecular Genetics and Mouse Models'. *Journal of Pediatric Endocrinology and Metabolism*, vol. 28, nos 1–2, Jan. 2015, <https://doi.org/10.1515/jpem-2014-0442>.
- Matthay, Katherine K., et al. 'Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-
-Retinoic Acid'. *New England Journal of Medicine*, vol. 341, no. 16, Oct. 1999, pp. 1165–73, <https://doi.org/10.1056/NEJM199910143411601>.
- Milne, Thomas A. 'Mouse Models of MLL Leukemia: Recapitulating the Human Disease'. *Blood*, vol. 129, no. 16, Apr. 2017, pp. 2217–23, <https://doi.org/10.1182/blood-2016-10-691428>.
- Morsut, Leonardo, et al. 'Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors'. *Cell*, vol. 164, no. 4, Feb. 2016, pp. 780–91, <https://doi.org/10.1016/j.cell.2016.01.012>.
- Mossé, Yaël P., et al. 'Identification of ALK as a Major Familial Neuroblastoma Predisposition Gene'. *Nature*, vol. 455, no. 7215, Oct. 2008, pp. 930–35, <https://doi.org/10.1038/nature07261>.
- Nataliya Zhukova. 'Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma'. *Journal of Clinical Oncology*, vol. 31, no. 23, 2013, <https://doi.org/10.1200/JCO.2012.48.5052>.
- Nature Reviews Immunology. vol. 12, no. 4, 2012, <https://www.nature.com/nri/volumes/12/issues/4>.
- Niemeyer, Charlotte Marie, and Christian Peter Kratz. 'Paediatric Myelodysplastic Syndromes and Juvenile Myelomonocytic Leukaemia: Molecular Classification and Treatment Options'. *British Journal of Haematology*, vol. 140, no. 6, Mar. 2008, pp. 610–24,

<https://doi.org/10.1111/j.1365-2141.2007.06958.x>.

Niklison-Chirou, Maria Victoria, et al. 'Tap73 Is a Marker of Glutamine Addiction in Medulloblastoma'. *Genes & Development*, vol. 31, no. 17, Sept. 2017, pp. 1738–53, <https://doi.org/10.1101/gad.302349.117>.

Northcott, Paul A., et al. 'The Clinical Implications of Medulloblastoma Subgroups'. *Nature Reviews Neurology*, vol. 8, no. 6, June 2012, pp. 340–51, <https://doi.org/10.1038/nrneurol.2012.78>.

O'Connor, David, et al. 'Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia'. *Journal of Clinical Oncology*, vol. 36, no. 1, Jan. 2018, pp. 34–43, <https://doi.org/10.1200/JCO.2017.74.0449>.
———. 'Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia'. *Journal of Clinical Oncology*, vol. 36, no. 1, Jan. 2018, pp. 34–43, <https://doi.org/10.1200/JCO.2017.74.0449>.

Pastorino, Fabio, et al. 'Ligand-Targeted Liposomal Therapies of Neuroblastoma'. *Current Medicinal Chemistry*, vol. 14, no. 29, Dec. 2007, pp. 3070–78, <https://doi.org/10.2174/092986707782793916>.

Pathania, Manav, et al. 'H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas'. *Cancer Cell*, vol. 32, no. 5, Nov. 2017, pp. 684–700.e9, <https://doi.org/10.1016/j.ccell.2017.09.014>.

Pfister, Stefan, et al. 'Novel Genomic Amplification Targeting the microRNA Cluster at 19q13.42 in a Pediatric Embryonal Tumor with Abundant Neuropil and True Rosettes'. *Acta Neuropathologica*, vol. 117, no. 4, Apr. 2009, pp. 457–64, <https://doi.org/10.1007/s00401-008-0467-y>.

Phoenix, Timothy N., et al. 'Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype'. *Cancer Cell*, vol. 29, no. 4, Apr. 2016, pp. 508–22, <https://doi.org/10.1016/j.ccell.2016.03.002>.

Qasim, Waseem, et al. 'Molecular Remission of Infant B-ALL after Infusion of Universal TALEN Gene-Edited CAR T Cells'. *Science Translational Medicine*, vol. 9, no. 374, Jan. 2017, <https://doi.org/10.1126/scitranslmed.aaj2013>.

Qiao, Jingbo, et al. 'PI3K/AKT and ERK Regulate Retinoic Acid-Induced Neuroblastoma Cellular Differentiation'. *Biochemical and Biophysical Research Communications*, vol. 424, no. 3, Aug. 2012, pp. 421–26, <https://doi.org/10.1016/j.bbrc.2012.06.125>.

Rasaiyaah, Jane, et al. 'TCR $\alpha\beta$ /CD3 Disruption Enables CD3-Specific Antileukemic T Cell Immunotherapy'. *JCI Insight*, vol. 3, no. 13, July 2018, <https://doi.org/10.1172/jci.insight.99442>.

Reynolds, C. Patrick, et al. 'Retinoid Therapy of High-Risk Neuroblastoma'. *Cancer Letters*, vol. 197, nos 1–2, July 2003, pp. 185–92, [https://doi.org/10.1016/S0304-3835\(03\)00108-3](https://doi.org/10.1016/S0304-3835(03)00108-3).

Richmond, A., and Y. Su. 'Mouse Xenograft Models vs GEM Models for Human Cancer

Therapeutics'. *Disease Models and Mechanisms*, vol. 1, nos 2–3, Sept. 2008, pp. 78–82, <https://doi.org/10.1242/dmm.000976>.

Sadelain, Michel, et al. 'Therapeutic T Cell Engineering'. *Nature*, vol. 545, no. 7655, May 2017, pp. 423–31, <https://doi.org/10.1038/nature22395>.

Schwab, M. 'MYCN in Neuronal Tumours'. *Cancer Letters*, vol. 204, no. 2, Feb. 2004, pp. 179–87, [https://doi.org/10.1016/S0304-3835\(03\)00454-3](https://doi.org/10.1016/S0304-3835(03)00454-3).

Schwalbe, Ed. C., et al. 'Histologically Defined Central Nervous System Primitive Neuro-Ectodermal Tumours (CNS-PNETs) Display Heterogeneous DNA Methylation Profiles and Show Relationships to Other Paediatric Brain Tumour Types'. *Acta Neuropathologica*, vol. 126, no. 6, Dec. 2013, pp. 943–46, <https://doi.org/10.1007/s00401-013-1206-6>.

Schwalbe, Edward C., et al. 'Novel Molecular Subgroups for Clinical Classification and Outcome Prediction in Childhood Medulloblastoma: A Cohort Study'. *The Lancet Oncology*, vol. 18, no. 7, July 2017, pp. 958–71, [https://doi.org/10.1016/S1470-2045\(17\)30243-7](https://doi.org/10.1016/S1470-2045(17)30243-7).

Schwartzentruber, Jeremy, et al. 'Driver Mutations in Histone H3.3 and Chromatin Remodelling Genes in Paediatric Glioblastoma'. *Nature*, vol. 482, no. 7384, Feb. 2012, pp. 226–31, <https://doi.org/10.1038/nature10833>.

Sidell, Neil. 'Retinoic Acid-Induced Growth Inhibition and Morphologic Differentiation of Human Neuroblastoma Cells In Vitro'. *JNCI: Journal of the National Cancer Institute*, 1982, <https://doi.org/10.1093/jnci/68.4.589>.

Slany, R. K. 'The Molecular Mechanics of Mixed Lineage Leukemia'. *Oncogene*, vol. 35, no. 40, Oct. 2016, pp. 5215–23, <https://doi.org/10.1038/onc.2016.30>.

Stone, T. J., and T. S. Jacques. 'Medulloblastoma: Selecting Children for Reduced Treatment'. *Neuropathology and Applied Neurobiology*, vol. 41, no. 2, Feb. 2015, pp. 106–08, <https://doi.org/10.1111/nan.12193>.

Strebhardt, Klaus, and Axel Ullrich. 'Paul Ehrlich's Magic Bullet Concept: 100 Years of Progress'. *Nature Reviews Cancer*, vol. 8, no. 6, June 2008, pp. 473–80, <https://doi.org/10.1038/nrc2394>.

Sturm, Dominik, Hendrik Witt, et al. 'Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma'. *Cancer Cell*, vol. 22, no. 4, Oct. 2012, pp. 425–37, <https://doi.org/10.1016/j.ccr.2012.08.024>.

Sturm, Dominik, Brent A. Orr, et al. 'New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs'. *Cell*, vol. 164, no. 5, Feb. 2016, pp. 1060–72, <https://doi.org/10.1016/j.cell.2016.01.015>.

Taylor, Michael D Northcott, Paul A Korshunov, Andrey Remke, Marc Cho, Yoon-jae. 'Molecular Subgroups of Medulloblastoma: The Current Consensus'. *Acta Neuropathologica*, vol. 123, no. 3, pp. 465–72, https://search.proquest.com/docview/928783888?rfr_id=info%3Axri%2Fsid%3Aprimo.

Vogelstein, B., et al. 'Cancer Genome Landscapes'. *Science*, vol. 339, no. 6127, Mar. 2013,

pp. 1546–58, <https://doi.org/10.1126/science.1235122>.

———. 'Cancer Genome Landscapes'. *Science*, vol. 339, no. 6127, Mar. 2013, pp. 1546–58, <https://doi.org/10.1126/science.1235122>.

Vora, Ajay, Nick Goulden, Chris Mitchell, et al. 'Augmented Post-Remission Therapy for a Minimal Residual Disease-Defined High-Risk Subgroup of Children and Young People with Clinical Standard-Risk and Intermediate-Risk Acute Lymphoblastic Leukaemia (UKALL 2003): A Randomised Controlled Trial'. *The Lancet Oncology*, vol. 15, no. 8, July 2014, pp. 809–18, [https://doi.org/10.1016/S1470-2045\(14\)70243-8](https://doi.org/10.1016/S1470-2045(14)70243-8).

Vora, Ajay, Nick Goulden, Rachel Wade, et al. 'Treatment Reduction for Children and Young Adults with Low-Risk Acute Lymphoblastic Leukaemia Defined by Minimal Residual Disease (UKALL 2003): A Randomised Controlled Trial'. *The Lancet Oncology*, vol. 14, no. 3, Mar. 2013, pp. 199–209, [https://doi.org/10.1016/S1470-2045\(12\)70600-9](https://doi.org/10.1016/S1470-2045(12)70600-9).

Wegman-Ostrosky, Talia, and Sharon A. Savage. 'The Genomics of Inherited Bone Marrow Failure: From Mechanism to the Clinic'. *British Journal of Haematology*, vol. 177, no. 4, May 2017, pp. 526–42, <https://doi.org/10.1111/bjh.14535>.

Weinberg, Robert A. *The Biology of Cancer*. 2nd ed, Garland Science, 2014.

Wright, James Homer. 'NEUROCYTOMA OR NEUROBLASTOMA, A KIND OF TUMOR NOT GENERALLY RECOGNIZED'. *The Journal of Experimental Medicine*, vol. 12, no. 4, 1910, <https://doi.org/10.1084/jem.12.4.556>.

Yang, LiqunKe, Xiao-XueXuan, FanTan, JuanHou, Jianbing. 'PHOX2B Is Associated with Neuroblastoma Cell Differentiation'. *Cancer Biotherapy & Radiopharmaceuticals*, vol. 31, pp. 44–51, <https://doi.org/10.1089/cbr.2015.1952>.

Yong, Carmen S. M., et al. 'CAR T-Cell Therapy of Solid Tumors'. *Immunology and Cell Biology*, vol. 95, no. 4, Apr. 2017, pp. 356–63, <https://doi.org/10.1038/icb.2016.128>.

Zelent, Arthur, et al. 'Role of the TEL-AML1 Fusion Gene in the Molecular Pathogenesis of Childhood Acute Lymphoblastic Leukaemia'. *Oncogene*, vol. 23, no. 24, May 2004, pp. 4275–83, <https://doi.org/10.1038/sj.onc.1207672>.

Zhu, Shizhen, et al. 'Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis'. *Cancer Cell*, vol. 21, no. 3, Mar. 2012, pp. 362–73, <https://doi.org/10.1016/j.ccr.2012.02.010>.